Mankind Pharma Limited — Dividend/Bonus, 31-07-2025: Dividend

Mankind Pharma's Board has approved an interim dividend of ₹1 per equity share for FY25-26, with August 8 set as the record date for payout within 30 days. This comes alongside approval of the financial results for the quarter. The company is also acquiring the Women Health Rx Business from its wholly-owned subsidiary, Bharat Serums and Vaccines, to streamline operations. Additionally, Mankind Pharma plans to raise up to ₹1,000 Cr via commercial papers for short-term funding and noted the resignation of its Chief Marketing Officer, Dr. Sanjay Koul. These moves indicate active strategic management and direct shareholder returns.